American Oriental Bioengineering, Inc.
AOBI
Rank in Stocks
#35104
American Oriental Bioengineering, Inc. (AOBI), headquartered in Beijing, China,... American Oriental Bioengineering, Inc. (AOBI), headquartered in Beijing, China, focuses its operations on the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical and healthcare products. The company's core pharmaceutical offerings include a range of prescription medications. Among these are the Shuanghuanglian Lyophilized Injection Powder (SHL brand), prescribed to treat flu symptoms such as elevated fever, coughs, and sore throats, as well as to address upper respiratory tract infections, mild pneumonia, bronchitis, and tonsillitis. Another significant prescription product is the Cease Enuresis Soft Gel (CE Gel brand), formulated to alleviate bedwetting. AOBI's portfolio also extends to various over-the-counter (OTC) pharmaceutical solutions. These feature the Cease Enuresis Patch for managing bedwetting and urinary incontinence; Jinji Capsule, used for conditions like endometritis, annexitis, and pelvic inflammations; Jinji Yimucao, designed to relieve premenstrual syndrome (PMS) and other related menstrual and menopausal discomforts; and Boke Nasal Spray, which offers relief for sinus congestion associated with the common cold, nasal stuffiness, chronic rhinitis, allergic rhinitis, and nasosinusitis. Furthermore, the company develops and markets a selection of nutraceutical products, notably including soybean peptide-based items available as beverages, tablets, powders, and instant coffee. Beyond its manufacturing activities, AOBI is also involved in the wholesale and retail distribution of both its pharmaceutical and nutraceutical goods. The company's products are sold across the People's Republic of China through both direct channels and a network of distributors, reaching hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical retailers, and various other retail outlets.
Share Price
$0.013
Last synced: 2026-11-10
Market Cap
$948.13
Change (1 day)
0.00%
Change (1 year)
983.33%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade American Oriental Bioengineering, Inc. (AOBI)
Category
Healthcare
Operating Margin for American Oriental Bioengineering, Inc. (AOBI)
Operating Margin as of November 2026 TTM: -37.89%
According to American Oriental Bioengineering, Inc.'s latest financial reports, its current operating margin (TTM) is -37.89%. At the end of 2012 the company had an operating margin of -37.89%.
Operating Margin history for American Oriental Bioengineering, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -37.89% | 0.00% |
| 2012 | -37.89% | 2,168.86% |
| 2011 | -1.67% | -116.82% |
| 2010 | 9.93% | -49.95% |
| 2009 | 19.84% | -17.30% |
| 2008 | 23.99% | -26.28% |
| 2007 | 32.54% | -1.45% |
| 2006 | 33.02% | -1.46% |
| 2005 | 33.51% | 6.65% |
| 2004 | 31.42% | 15.05% |
| 2003 | 27.31% | 60.74% |
| 2002 | 16.99% | -7.31% |
| 2001 | 18.33% | -100.50% |
| 2000 | -3,668.99% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -101.02% |
US
|
|
| -149.01% | -96.07% |
US
|
|
| 25.57% | -100.67% |
AU
|
|
| 31.23% | -100.82% |
BE
|
|
| 29.35% | -100.77% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about American Oriental Bioengineering, Inc.'s operating margin
What is American Oriental Bioengineering, Inc.'s operating margin?
American Oriental Bioengineering, Inc.'s operating margin is -37.89%, as of Nov 2026.
What was American Oriental Bioengineering, Inc.'s operating margin in 2012?
In 2012, American Oriental Bioengineering, Inc.'s operating margin was -37.89%, compared with -1.67% in 2011.
How has American Oriental Bioengineering, Inc.'s operating margin changed since 2007?
From 2007 to 2012, American Oriental Bioengineering, Inc.'s operating margin was highest in 2007 (32.54%) and lowest in 2012 (-37.89%).
How does American Oriental Bioengineering, Inc.'s operating margin compare with similar companies?
American Oriental Bioengineering, Inc.'s operating margin (-37.89%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.